Quick Answer
Inhibikase Therapeutics, Inc. reported Net Income of -$48.26 million for fiscal year 2025.
Inhibikase Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$48.26M | -75.4% |
| 2024 | -$27.52M | -44.6% |
| 2023 | -$19.03M | -5.4% |
| 2022 | -$18.05M | -22.1% |
| 2021 | -$14.79M | -419.2% |
| 2020 | -$2.85M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$11.93M | -106.5% | -20.3% |
| June 30, 2025 | -$9.92M | -99.9% | +27.5% |
| March 31, 2025 | -$13.68M | -194.2% | -136.7% |
| September 30, 2024 | -$5.78M | -25.7% | -16.5% |
| June 30, 2024 | -$4.96M | +14.2% | -6.7% |
| March 31, 2024 | -$4.65M | -3.8% | -1.2% |
| September 30, 2023 | -$4.60M | -2.2% | +20.5% |
| June 30, 2023 | -$5.78M | -24.5% | -29.0% |
- Inhibikase Therapeutics, Inc. showed a decrease of -75.4% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Inhibikase Therapeutics, Inc.’s net income has declined by 1594.6% (from -$2.85 million to -$48.26 million).
- The most recent figure is from Inhibikase Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: